Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | CBLB | Q13191 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 3/20 | 0.34 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.33 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
| ▸ | CSNK2A1 | P68400 | 3/20 | 0.32 |
| ▸ | APAF1 | O14727 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18806993 | 1.00 | MAPK1 (0.49) | MAPK1ALDH1A1CBLBHTTCYP1A2 | |
| SCHEMBL6154816 | 0.83 | MAPK1 (0.47) | MAPK1ALDH1A1CBLBCYP1A2CYP2C19 | |
| SCHEMBL22143639 | 0.82 | MAPK1 (0.56) | MAPK1ALDH1A1HTTCYP1A2CYP2C19 | |
| SCHEMBL22516955 | 0.81 | MAPK1 (0.46) | MAPK1ALDH1A1CBLBHTTCYP1A2 | |
| SCHEMBL12512974 | 0.80 | MAPK1 (0.44) | MAPK1ALDH1A1CBLBHTTCYP1A2 | |
| SCHEMBL12434717 | 0.80 | MAPK1 (0.44) | MAPK1ALDH1A1CBLBHTTCYP1A2 | |
| SCHEMBL8141395 | 0.80 | MAPK1 (0.44) | MAPK1ALDH1A1CBLBHTTCYP1A2 | |
| SCHEMBL21587664 | 0.78 | MAPK1 (0.46) | MAPK1ALDH1A1CBLBHTTCYP1A2 | |
| SCHEMBL31030379 | 0.77 | MAPK1 (0.42) | MAPK1ALDH1A1CYP1A2CYP2C19KDM4E | |
| SCHEMBL22781298 | 0.75 | CNR2 (0.44) | MAPK1ALDH1A1CBLBCYP1A2CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260049080-A1 | WILD TYPE KIT INHIBITORS | BLUEPRINT MEDICINES CORP (US) | 2026-02-19 | — | — | US | disclosed |
| US-12448379-B2 | Wild type kit inhibitors | BLUEPRINT MEDICINES CORPORATION (US) | 2025-10-21 | — | — | US | disclosed |
| US-20240262826-A1 | WILD TYPE KIT INHIBITORS | BLUEPRINT MEDICINES CORPORATION | 2024-08-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260049080-A1 | WILD TYPE KIT INHIBITORS | KIT, CSNK1A1, CSNK1A1L | MAPK1 171/4885ALDH1A1 741/4885CBLB 701/4885 |
| US-12448379-B2 | Wild type kit inhibitors | KIT, TNK1, TNNI3K | MAPK1 65/4885ALDH1A1 1830/4885CBLB 683/4885 |
| US-20240262826-A1 | WILD TYPE KIT INHIBITORS | KIT, TNK1, TNNI3K | MAPK1 65/4885ALDH1A1 1830/4885CBLB 683/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.